

Agenda
ORD Team Meeting
Strengthening Transparency in Regulatory Science
September 5, 2018

- 1) Overview
- 2) Issues
 - a. PII
 - b. Dose-response models
 - c. Assessing the validity of prior epidemiologic studies (without public access to data and analytic methods)
 - d. Infrastructure
 - e. Requirements for cooperative agreements and grants
 - f. Replication/reproducibility
 - g. Proprietary models
 - h. Specific chemicals

Attachments

Public comments (examples)

- 1) Yale Law School/Yale School of Medicine/Yale School of Public Health Collaboration for Research Integrity and Transparency (CRIT)
 - a. Highlighted Issues: 1) Data sharing; 2) Replication/reproducibility; 3) Non-linear dose-response models
- 2) American Chemistry Council
 - a. Highlighted issues: 1) Reproducibility; 2) Data and model access requirements for Cooperative Agreements and Grants; 3) Providing protected access to sensitive and confidential data; 4) IRIS
- 3) Electric Power Research Institute, Inc (EPRI)
 - a. Highlighted issues: 1) PII; 2) Dose-response models; 3) Costs associated with making information public; 3) Definition of data; 4) Use of standardized methodology
- 4) NRDC
 - a. Highlighted issues: 1) Proprietary models; 2) Chemicals